World Congress

Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®

Retrieved on:

Thursday, June 22, 2023

Presentation of the full dataset will be planned for a medical meeting in Q4 2023.

Key Points:

Presentation of the full dataset will be planned for a medical meeting in Q4 2023.
“Concluding this Phase 2 clinical study marks another significant milestone for Evolus and our commitment to delivering continued product innovation,” said Rui Avelar, M.D., Chief Medical Officer and Head of Research and Development, Evolus.
The study has three arms: Jeuveau Extra-Strength 40U and two active controls, BOTOX® 20U and Jeuveau 20U.
Through the company’s TRANSPARENCY Clinical Program, Jeuveau was clinically proven to temporarily improve moderate to severe glabellar lines or “11’s” in adults and included the largest head-to-head pivotal study versus BOTOX®.

Valid collaborates with Cobira to empower interconnectivity between Private and Public Networks

Retrieved on:

Monday, June 5, 2023

MADRID, June 5, 2023 /PRNewswire/ -- Valid, the champion of interoperable eSIM services, has joined forces with Cobira, a trusted B2B secure IoT connectivity provider, to introduce their ground-breaking Private Networks Offering. This solution empowers IoT/M2M and consumer devices to seamlessly transition between public and designated private networks and maintain uninterrupted connectivity.

Key Points:

This solution empowers IoT/M2M and consumer devices to seamlessly transition between public and designated private networks and maintain uninterrupted connectivity.
"Our new solution, developed in partnership with Cobira and our dedicated consulting services, streamlines the interworking between private and public networks.
The collaboration between Valid and Cobira sets the stage for revolutionizing connectivity experiences, enabling IoT and consumer devices to operate seamlessly across private and public networks.
For more information about the Private Networks offering and the collaborative efforts of Valid and Cobira, please visit www.valid.com .

Valid collaborates with Cobira to empower interconnectivity between Private and Public Networks

Retrieved on:

Monday, June 5, 2023

MADRID, June 5, 2023 /PRNewswire/ -- Valid, the champion of interoperable eSIM services, has joined forces with Cobira, a trusted B2B secure IoT connectivity provider, to introduce their ground-breaking Private Networks Offering. This solution empowers IoT/M2M and consumer devices to seamlessly transition between public and designated private networks and maintain uninterrupted connectivity.

Key Points:

This solution empowers IoT/M2M and consumer devices to seamlessly transition between public and designated private networks and maintain uninterrupted connectivity.
"Our new solution, developed in partnership with Cobira and our dedicated consulting services, streamlines the interworking between private and public networks.
The collaboration between Valid and Cobira sets the stage for revolutionizing connectivity experiences, enabling IoT and consumer devices to operate seamlessly across private and public networks.
For more information about the Private Networks offering and the collaborative efforts of Valid and Cobira, please visit www.valid.com .

IPLOOK Will Return to MVNOs World Congress in Amsterdam

Retrieved on:

Monday, May 22, 2023

Congress, Mobile virtual network operator, World Congress, MVNO, MVNE, Mobile telephony

HONG KONG, May 22, 2023 /PRNewswire/ -- IPLOOK is excited to announce its return to the MVNOs World Congress, after a successful participation four years ago in Madrid. This year, the MVNOs World Congress will take place in Amsterdam from June 5th to 7th, and IPLOOK invites industry professionals to join this remarkable gathering to foster networking, collaboration, and knowledge sharing at Stand 23.

Key Points:

HONG KONG, May 22, 2023 /PRNewswire/ -- IPLOOK is excited to announce its return to the MVNOs World Congress, after a successful participation four years ago in Madrid.
This year, the MVNOs World Congress will take place in Amsterdam from June 5th to 7th, and IPLOOK invites industry professionals to join this remarkable gathering to foster networking, collaboration, and knowledge sharing at Stand 23 .
At the MVNOs World Congress, IPLOOK will proudly showcase its innovative solutions, demonstrating the numerous advantages they bring to MVNO operators.
IPLOOK extends a warm invitation to all MVNOs and industry players attending the MVNOs World Congress in Amsterdam.

Kyowa Kirin Presents New Findings from Real-World Study in Parkinson's Disease at the 2023 IAPRD Conference

Retrieved on:

Friday, May 12, 2023

PD, Polypharmacy, International Association, Parkinson, Kyowa Kirin, Parkinson's disease, Patient, L-DOPA, World Congress, TSE, Pharmaceutical industry, Parkinsonism

Findings to be presented at International Association of Parkinsonism and Related Disorders (IARPD) 2023 World Congress being held May 13-16, 2023.

Key Points:

Findings to be presented at International Association of Parkinsonism and Related Disorders (IARPD) 2023 World Congress being held May 13-16, 2023.
BEDMINSTER, N.J., May 12, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company, will share results from a retrospective study evaluating real-world utilization of istradefylline along with other Parkinson's disease (PD) medications among patients with PD.1 These findings will be presented on Sunday, May 14 from 12:15 - 1:15 PM CDT at the International Association of Parkinsonism and Related Disorders (IAPRD) conference in Chicago, Illinois.
As PD progresses, approximately 50% of patients will experience off time, which is a return of Parkinson's disease symptoms between doses of levodopa within 5 years of initiating levodopa treatment.
2,3,4NOURIANZ® (istradefylline) is prescription medication indicated as adjunctive treatment to levodopa/carbidopa in adult patients with PD experiencing "off" episodes.

Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events

Retrieved on:

Monday, April 17, 2023

Essential tremor, Central nervous system, Event, AAN, Tolerability, Efficacy, Media, American Academy, CNS, Clinical trial, MA, Webcast, ITC, World Congress, Conference, Treatment, Pharmaceutical industry, Safety

BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the following upcoming ulixacaltamide presentations and events focused on Essential Tremor (ET):

Key Points:

BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the following upcoming ulixacaltamide presentations and events focused on Essential Tremor (ET):
75th Annual American Academy of Neurology (AAN), Boston, MA
World Congress on Parkinson’s Disease and Related Disorders 2023 (IAPRD), Chicago, IL
Title: Essential1: Results from a Phase 2 Trial Evaluating the Tolerability, Safety and Efficacy of Ulixacaltamide in Adults with Essential Tremor
2nd International Tremor Conference (ITC), New York, NY
Title: Essential 1: Results from a Phase 2 Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Clinical Trial to Evaluate the Tolerability, Safety, and Efficacy of Ulixacaltamide in the Treatment of Adults with Essential Tremor
The company hosted event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com .
A replay of the webcast will be available on Praxis’ website for 90 days following the event.

Turn Biotechnologies Introduces its Dermatology Platform to the European Aesthetic Community at AMWC

Retrieved on:

Thursday, March 30, 2023

CET, Cell, Doctor of Philosophy, Messenger, Grimaldi Forum, Congress, Dermatology, Aesthetics, World Congress, Epigenetics, Skin, Mobile phone, Ageing

MOUNTAIN VIEW, Calif., March 30, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, announced that it will for the first time share new data for its revolutionary dermatology platform with the international regenerative aesthetic community.

Key Points:

MOUNTAIN VIEW, Calif., March 30, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, announced that it will for the first time share new data for its revolutionary dermatology platform with the international regenerative aesthetic community.
Evidence-based data showing the global regenerative efficacy of Turn Bio's Epigenetic Reprogramming of Aging (ERA™) technology on human skin cells will be shared at the Aesthetic and Anti-aging World Congress, the leading international conference specializing in aesthetic regenerative and anti-aging medicine.
Turn Bio's co-founder and head of research Vittorio Sebastiano, PhD, will provide insights on stem cell exhaustion and discuss how the company's ERA™ technology can rejuvenate cells and restore cellular function in skin.
The latest Turn Bio dermatology data will also be discussed in presentations by several dermatology key opinion leaders during scientific sessions chaired by internationally recognized experts in the field.

Turn Biotechnologies Introduces its Dermatology Platform to the European Aesthetic Community at AMWC

Retrieved on:

Thursday, March 30, 2023

CET, Cell, Doctor of Philosophy, Messenger, Grimaldi Forum, Congress, Dermatology, Aesthetics, World Congress, Epigenetics, Skin, Mobile phone, Ageing

MOUNTAIN VIEW, Calif., March 30, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, announced that it will for the first time share new data for its revolutionary dermatology platform with the international regenerative aesthetic community.

Key Points:

MOUNTAIN VIEW, Calif., March 30, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, announced that it will for the first time share new data for its revolutionary dermatology platform with the international regenerative aesthetic community.
Evidence-based data showing the global regenerative efficacy of Turn Bio's Epigenetic Reprogramming of Aging (ERA™) technology on human skin cells will be shared at the Aesthetic and Anti-aging World Congress, the leading international conference specializing in aesthetic regenerative and anti-aging medicine.
Turn Bio's co-founder and head of research Vittorio Sebastiano, PhD, will provide insights on stem cell exhaustion and discuss how the company's ERA™ technology can rejuvenate cells and restore cellular function in skin.
The latest Turn Bio dermatology data will also be discussed in presentations by several dermatology key opinion leaders during scientific sessions chaired by internationally recognized experts in the field.

Xalud Therapeutics Presents Clinical Data on XT-150 in Knee Osteoarthritis at the 2023 Osteoarthritis Research Society International World Congress

Retrieved on:

Monday, March 20, 2023

NEW YORK, March 20, 2023 (GLOBE NEWSWIRE) -- Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, today announced pooled gait data from a world-renowned gait laboratory in Adelaide, Australia, which served as a study site for two studies of lead candidate XT-150 in patients with knee osteoarthritis (OA). XT-150 is a locally injectable plasmid DNA (pDNA)-delivered gene therapy expressing IL-10v, a proprietary modified version of interleukin-10 (IL-10), which Xalud is evaluating across a broad range of chronic inflammatory diseases in clinical and preclinical studies.

Key Points:

The results demonstrate a positive signal supporting the use of XT-150 as a potential effective treatment in knee OA with the goal of improving joint function.
The data were presented in a poster presentation titled “Functional improvements in knee kinematics during walking gait over six months following treatment with XT-150: pooled results from two clinical trials” at the 2023 Osteoarthritis Research Society International (OARSI) World Congress.
We believe that this supplements the body’s own IL-10 activity and may restore immune system homeostasis in chronic inflammatory diseases such as knee OA.
Xalud has included gait analysis as part of its multi-study development program to provide functional assessment in addition to patient reported outcomes.

New data by AKL Therapeutics suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

Retrieved on:

Monday, March 20, 2023

STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3

Key Points:

STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3
The study, using a human chondrocyte (cartilage-forming) cell line, was carried out at the Institute of Biomedical Research of A Coruña (INIBIC) in Spain.1 It found that APPA appears to not only reduce the number of harmful senescent cells which build up in the cartilage causing inflammation (a 'senolytic' effect), but could also potentially reverse the senescence process so cells can function normally again (a 'senomorphic' effect).1,4
Alan Reynolds, Chief Scientific Officer at AKL Therapeutics, says: "These latest findings raise the tantalising possibility that APPA could modify the progression of debilitating OA for patients by eliminating or delaying the adverse effects of cellular senescence and the process of ageing.3
"Frailty and mobility issues have a significant impact as we age, often leading to people living many years in pain and ill health.5,6 If we can reduce senescence, which contributes to joint damage in OA7 and is involved in many other age-related diseases, we can hopefully help improve peoples' healthspan, so they age in better physical and mental health.
"8
As we age, dysfunctional senescent cells – often dubbed "zombie" cells – build up in the body while secreting harmful chemicals which cause inflammation and damage surrounding tissue – a process known as senescence.2 They have become one of the most promising targets for healthy ageing research as senescence is now known to play a major role in the development of many age-related diseases, including OA, Chronic Obstructive Pulmonary Disease (COPD), Alzheimer's Disease, Parkinson's Disease, osteoporosis, and diabetes.9
Developing a new class of drugs called senotherapeutics to eliminate or delay the damaging effects of this cellular senescence is a new frontier in medicine.10 Senotherapeutics have the potential to increase healthspan by delaying the worse effects of ageing, which would reduce the burden of age-related diseases and could save healthcare systems billions every year.11
David Miles, Chief Executive Officer at AKL Therapeutics, says: "With a unique mechanism of action,12-15 APPA is the only oral drug that targets the multiple signalling pathways in bone, cartilage and inflammation involved in OA, delivering pain relief to multiple joints.
With this latest data now showing that APPA has a potential senomorphic effect, we've recently filed a patent application and will look to carry out further studies on other senescence-related diseases to investigate its potential as a senotherapeutic."
APPA is an oral, patented, fixed-dose combination of two synthetically produced, synergistic, secondary metabolites of plant origin.16,17Previous human clinical trials have shown that APPA has a good safety profile, is well-tolerated and reduces pain in OA.18,19 Importantly, it has been shown to reduce levels of cartilage-damaging enzymes and levels of bone destruction.13-15 The Phase 2a trial found that those with more severe disease benefited most from APPA with a statistically significant improvement in pain vs placebo.18
There are currently no effective and well tolerated oral therapies that provide long-term pain relief or reduce the progression of OA, a common, debilitating, degenerative disease of the joints involving the cartilage, bone, and its surrounding tissues.22 OA is the most common joint disease worldwide, affecting an estimated 10% of men and 18% of women over 60 years of age.23 Globally, the prevalent cases of OA increased by 113.25%, from 247.51 million in 1990 to 527.81 million in 2019, with OA of the knee contributing most to the overall burden.24